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INTRODUCTION
Schizophrenia is a complex disorder involving multiple ge-
netic and environmental factors [1]. Despite accumulating evi-
dence suggesting that the etiology of schizophrenia includes
a highly heritable component [2], the specific genetic loci and
neurobiological mechanisms that contribute to the disorder
remain unclear. 
A number of studies have evaluated the association bet-
ween the Val108/158Met polymorphism (rs4680) in the COMT
gene, encoding catechol-O-methyltransferase, which catalyzes
the metabolism of dopamine, and schizophrenia risk. Although
several functional studies have shown that patients with the
Val/Val genotype had better executive function and working
memory compared to Met allele carriers [3, 4], recent meta-
analyses could not replicate the association in either European
or Asian populations [5-7]. Another variant in the 3′ untrans-
lated region (rs165599) in the COMT gene, which was highly
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associated with schizophrenia in a large study conducted in a
population of Israelis of Ashkenazi descent [8], has been re-
ported to differentially affect the expression of Val108/158Met
alleles in human brain tissue [9]. 
The MTHFR gene, encoding methylenetetrahydrofolate
reductase, which plays an important role in folate metabolism
[10], is known to have two single nucleotide polymorphisms
(SNPs; C677T and A1298C) affecting enzyme activity [11,
12]. The MTHFR 677T variant showed a 35% reduction in
MTHFR activity such as DNA methylation [13, 14]. A recent
meta-analysis supports the association between MTHFR C677T
and A1298C SNPs and the development of schizophrenia
[15-18]. 
The metabolic pathways of COMT and MTHFR are inter-
connected [19]. Genetic variation in MTHFR could influence
the expression of COMT function through DNA methylation
of the COMT promoter region [20]. COMT promoter methy-
lation deficits have been described in schizophrenia, with con-
cordant increases in COMT expression [21]. It has been sug-
gested that abnormal methylation contributes to executive
dysfunction in schizophrenia and other psychiatric disorders
through downstream effects on dopamine signaling [22]. 
In the present study, we examined the relationship between
functional polymorphisms in COMT and MTHFR polymor-
phisms and schizophrenia risk. We also investigated the effect
of the combined genotypes of COMT and MTHFR polymor-
phisms. 
SUBJECTS AND METHODS
Study subjects
A total of 360 patients with chronic schizophrenia and 348
healthy controls matched by age and sex were recruited from
the inpatient and outpatient clinical services of the Depart-
ment of Psychiatry, Dong-A University Hospital and other
university-affiliated hospitals of Busan City Psychiatric Cen-
ter. Schizophrenia was diagnosed on the basis of a clinical
interview, using the Comprehensive Assessment of Symp-
toms and History (CASH) [23]. All patients met the DSM-IV
criteria for schizophrenia [24]. The DSM-IV-diagnosed schizo-
phrenic patients were recruited to the study between Jan 2003
and Dec 2009 from the inpatient population. Patients were
selected according to strict criteria and those with both a cur-
rent and past history of aggressive behavior. Healthy adult
Korean volunteers were recruited as controls from among
the residents of Busan when receiving health checkups. They
had no reported current or past history of psychiatric disor-
ders, including significant violent episodes. The demographic
data for the case-control study is as follows: 54% male cases
and 56% male controls (p=0.948), with a mean age of 38.32
±3.93 yr for the cases and 38.26±5.51 for the controls
(p=0.866). This study design was approved by the Commit-
tee on Human Research of the Dong-A University Hospital
(Dong-A University IRB 07-18) and written informed con-
sent was obtained from all participants or their legal guardians.
DNA extraction and COMT/MTHFR genotyping
Blood samples were collected in tubes that contained EDTA.
Genomic DNA was extracted from white blood cell fractions
by means of a Qiagen blood kit (Qiagen, Chatsworth, CA,
USA). All four SNPs selected in this study were genotyped
by SNP-IT
TM assays using the SNPstream 25K
TM System, which
has been customized to perform fully automated genotyping
using samples in 384-well plates with a colorimetric readout
(Orchid Biosciences, New Jersey, USA). 
Briefly, for each SNP, a set of three primers was designed:
two PCR primers were selected to amplify a 100-200 base
pair product under standard conditions and a single-base pri-
mer extension (SBE) primer was designed to be approximately
25 bp in length on one side of the SNP site. Automated liq-
uid handling robotics was used to set up 5 mL PCR reactions
in 384-well plates. Each PCR reaction contained: 10.0 ng of
DNA, 1X PCR buffer, 0.125 units of AmpliTaq Gold DNA
polymerase (ABI, USA), 3.0 mM MgCl2, 0.25 mM of each
dNTP, and 0.5 pmol of each primer. Reactions were incubat-
ed at 95℃ for 10 min, then cycled 35 times at (95℃ for 30 s,
50, 55 or 60℃ for 1 min, 72℃ for 1 min) followed by 72℃
for 5 min. An annealing temperature of 50, 55 or 60℃ was
chosen as appropriate. The primer sequences are shown in
Table 1. 
The amplified PCR products were digested with T7 exonu-
clease (0.45 U/mL) at room temperature for 30 min. The 5′
phosphothioates on one of the PCR primers protected one
strand of the PCR product from T7 exonuclease digestion,
resulting in the generation of a single-stranded PCR product.
The single-stranded PCR product was hybridized to a 384-
well plate that contained a covalently attached SNP-IT
TM pri-
mer extension primer designed to hybridize immediately adja-
cent to the SNP. After hybridization, the SNP-IT
TM primer
was extended for a single base with the Klenow fragment of
DNA polymerase I and a mixture of appropriately labeled
terminating nucleotides, which were labeled with either FITC
or biotin and were complementary to the SNP. The identity
of the incorporated nucleotide was determined using serial
colorimetric reactions with anti-FITC-AP (alkaline phospha-
tase) and streptavidin-HRP (horseradish peroxidase) using p-
nitrophenyl phosphate (PNPP) and tetramethylbenzidine
(TMB) as a substrate respectively. 
The results of yellow and/or blue color developments foreach sample (wells) were analyzed in an ELISA reader and
the final genotype calls were automatically assigned using the
QCReview
TM program (Orchid Biosciences). Automated geno-
type calls were corroborated by visual inspection of the data.
Statistical analyses
The chi-square test was used to identify departures from
the Hardy-Weinberg equilibrium among the controls. To esti-
mate the relative risk of schizophrenia in relation to SNP geno-
type, odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated using unconditional logistic regression. The
homozygote of the most common allele in the subjects was
used as the reference and a p value <0.05 was considered sta-
tistically significant. 
Stratified analyses were also conducted to evaluate whether
the association between the SNPs and schizophrenia risk was
derived from the different ages and genders. All statistical anal-
yses were performed using SAS version 9.1 (SAS Inc., Cary,
NC, USA). 
RESULTS
The distribution of age and gender was similar between
cases and controls. The mean age was 38.3±3.9 in the cases,
and 38.3±5.5 in the controls. The proportion of male sub-
jects was 55% and 56% for cases and controls, respectively
(data not shown). All genotype frequencies of the four SNPs,
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COMT rs4680 (Val158Met) Forward ATCAACCCCGACTGTGCC 55
Reverse CTTTTTCCAGGTCTGACAACG
Extension 5′ FAM -GCGGATGGTGGATTTCGCTGGC
rs165599 (3′ -flanking region) Forward TCCTGCAGCTAGGCCAGG 55
Reverse AGAAAGGTGTGAATGCTGG
Extension 5′ FAM -GCTGACTCCTCTTCGTTTCCCAGGC
MTHFR rs1801133 (C677T) Forward AAGCAGGGAGCTTTGAGGC 55
Reverse CAAGTGATGCCCATGTCG
Extension 5′ FAM -GAAAAGCTGCGTGATGATGAAATCG
rs1801131 (A1298C) Forward AAGGAGGAGCTGCTGAAGA 55
Reverse TTTGTGACCATTCCGGTT
Extension 5′ FAM -TAAAGAACAAAGACTTCAAAGACACTT
Genes SNPs Primers Sequences (5′ 3′ ) Annealing temp (℃)
Table 1. Primer sequences for genotyping
COMT rs4680 GG 192 55.2 194 53.9 1.00* - - -
GA 132 37.9 139 38.6 1.04 0.76 1.42 0.79 
AA 24 6.9 27 7.5 1.11 0.62 2.00 0.72 
rs165599 GG 76 21.8 66 18.3 1.00* - - -
GA 160 46.0 184 51.1 1.32 0.89 1.96 0.16 
AA 112 32.2 110 30.6 1.13 0.74 1.72 0.57 
MTHFR rs1801133 CC 130 37.4 125 34.7 1.00* - - -
CT 158 45.4 176 48.9 1.16 0.84 1.61 0.38
TT 60 17.2 59 16.4 1.02 0.66 1.60 0.92 
rs1801131 AA 239 68.7 248 68.9 1.00* - - -
CA 100 28.7 105 29.2 1.01 0.73 1.40 0.94 
CC 9 2.6 7 1.9 0.75 0.28 2.05 0.57
N (%)
Controls (n=348)  Patients (n=360)
n% n %
Genes SNPs Genotype OR 95%  CI  p-value
Table 2. Genotype frequencies of selected polymorphisms in COMT and MTHFR among cases and controls
OR, odds ratio; CI, confidence interval; COMT, catechol-O-methyltransferase; MTHFR, methylenetetrahydrofolate reductase.
*Reference category, OR=1.
COMT, catechol-O-methyltransferase; MTHFR, methylenetetrahydrofolate reductase.4
COMT Val158Met (rs4680), rs165599 and MTHFR C677T
(rs1801133), and A1298C (rs1801131), were consistent with
the Hardy-Weinberg equilibrium in the control group (p>0.05).
As shown in Table 2, the genotype frequencies of the COMT
Val158Met and rs165599 did not differ between the patients
and controls. Likewise, the genotype frequencies of the MT-
HFR C677T and A1298C did not differ between the patients
and controls. 
No association was found either in the stratified analyses
by gender-difference (Table 3), or in the analyses of combined
genotypes (Table 4). In addition, we found no evidence of an
interactive effect between COMT Val158Met and MTHFR
C677T in the patients and controls (Table 5).
DISCUSSION
In our study, no association was found between the four
functional SNPs in COMT and MTHFR, and schizophrenia
risk in a Korean population. 
Although a number of previous studies have evaluated the
association between SNPs in the COMT gene, particularly a
well-known polymorphism at COMT Val158Met termed
rs4680, and schizophrenia, the results have been inconsistent
and recent meta-analyses found no evidence for a relation-
ship between COMT and schizophrenia [5-7, 25]. Several
reports suggest an association with the highly active Val allele
[3, 26], but many other studies have found no significant asso-
ciation [6, 27-29]. In our results, the COMT Val158Met geno-
type frequency was founded by 53.9% for GG (Val), 38.6%
for GA (Val/Met) and 7.5% for AA (Met) in schizophrenia.
These frequencies did not differ significantly with control
subjects (55.2% for GG, 37.9% for GA and 6.9% for AA).
This results were similar with that of previous studies con-
ducted on Korean populations (schizophrenia: 61% for GG,
31% for GA and 7% for AA; Control: 52% for GG, 39%
Epidemiology and Health 2010;32:e2010011
N (%)
Controls (n=348)  Patients (n=360)
n% n %
Genes SNPs  Sex  Genotype OR 95% CI p-value
Table 3. Stratified analysis by gender for the association between selected polymorphisms in COMT and MTHFR and schizophrenia
risk
OR, odds ratio; CI, confidence interval; COMT, catechol-O-methyltransferase; MTHFR, methylenetetrahydrofolate reductase.
*Reference category, OR=1.
COMT rs4680 Male GG 114 58.2 105 53.8 1.00* - - -
GA 66 33.7 75 38.5 1.23 0.81 1.86 0.33 
AA 16 8.2 15 7.7 1.02 0.49 2.16 0.96 
rs165599 GG 40 20.4 35 17.9 1.00* - - -
GA 86 43.9 107 54.9 1.42 0.83 2.43 0.18 
AA 70 35.7 53 27.2 0.87 0.49 1.54 0.62 
MTHFR rs1801133 CC 79 40.3 71 36.4 1.00* - - -
CT 81 41.3 88 45.1 1.21 0.78 1.88 0.40
TT 36 18.4 36 18.5 1.11 0.63 1.95 0.71 
rs1801131 AA 134 68.4 140 71.8 1.00* - - -
CA 58 29.6 51 26.2 0.84 0.54 1.31 0.45 
CC 4 2.0 4 2.1 0.96 0.24 3.91 0.95 
COMT rs4680 Female GG 78 51.3 89 54.3 1.00* - - -
GA 66 43.4 63 38.4 0.84 0.53 1.33 0.45 
AA 8 5.3 12 7.3 1.32 0.51 3.38 0.57 
rs165599 GG 36 23.7 30 18.3 1.00* - - -
GA 74 48.7 77 47.0 1.25 0.70 2.23 0.45 
AA 42 27.6 57 34.8 1.63 0.88 3.05 0.13 
MTHFR rs1801133 CC 51 33.6 54 32.9 1.00* - - -
CT 77 50.7 87 53.0 1.07 0.65 1.74 0.80
TT 24 15.8 23 14.0 0.91 0.46 1.80 0.78 
rs1801131 AA 105 69.1 107 65.2 1.00* - - -
CA 42 27.6 54 32.9 1.26 0.78 2.05 0.35
CC 5 3.3 3 1.8 0.59 0.14 2.53 0.48 for GA and 9% for AA) [30]. And the no significant associa-
tion for this SNP with schizophrenia was similar among sev-
eral Asian subjects but very different among several European
subjects [6, 31-33]. Overall, the Val allele may be a small risk
factor for schizophrenia in European populations, while case-
control studies have shown no association between Val158Met
and schizophrenia in Asian populations, and thus the results
remain inconclusive. 
Another candidate polymorphism in the 3′ -flanking region
(rs165599) was not associated with schizophrenia risk in our
study. The 3′ -flanking region of SNP rs165599 exhibited sig-
nificant allelic differences in expression in the human brain,
and the A allele in schizophrenia patients is associated with
higher expression of the COMT gene [9]. A previous study
by Chien et al. [34] reported that rs165599 was associated
with a family study, but there was no significant association in
a case-control study. Okochi et al. [25] reported that there was
no association between four major functional SNPs (rs2075-
507, rs737865, rs6267 and rs165599) and schizophrenia in a
Japanese population. Therefore, these results indicate that the
Val/Met polymorphism and three other functional SNPs may
not play a major role in schizophrenia.
In addition, Roffman et al. [35] reported that there was con-
tributed to the lack of association between Val158Met and
rs165599 and schizophrenia, which may have gender-specif-
ic differences, as there is a stronger association of the G (Val)
allele with schizophrenia in females [8]. Meyer-Lindenberg et
al. found that the Val158Met genotype involved an interaction
between rs2097603 at the P2 promoter region and rs165599
in the 3′ -flanking region. These interactions have been impli-
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N (%)
Controls (n=348) Patients (n=360)
Genes Genotype OR 95% CI p-value
Table 4. Distribution of combined genotypes of COMT Val158Met, rs165599 and MTHFR C677T, A1298C among cases and controls
OR, odds ratio; CI, confidence interval; COMT, catechol-O-methyltransferase; MTHFR, methylenetetrahydrofolate reductase.
*Reference category, OR=1, Val genotype; GG, Met carrier genotype; GA+AA.
N (%)
Controls (n=348) Patients (n=360)
n% n %
Genes
MTHFR
rs1801133
OR 95% CI p-value
Table 5. Interactive effects between COMT Val158Met and MTHFR C677T on schizophrenia risk
OR, odds ratio; CI, confidence interval; COMT, catechol-O-methyltransferase; MTHFR, methylenetetrahydrofolate reductase.
*Reference category, OR=1, Val genotype; GG, Met carrier genotype; GA+AA.
COMT Val CC 69 35.9 62 32.0 1.00* - - -
rs4680 CT 97 50.5 100 51.5 1.15 0.74 1.79 0.54 
TT 26 13.5 32 16.5 1.37 0.74 2.55 0.32
Met carrier CC 61 39.1 63 38.0 1.00* - - -
CT 61 39.1 76 45.8 1.21 0.74 1.96 0.45 
TT 34 21.8 27 16.3 0.77 0.42 1.42 0.40 
COMT rs4680 rs165599 n % n %
Val GG 65 33.9 57 29.4 1.00* - - -
GA 85 44.3 100 51.5 1.34 0.85 2.12 0.20 
AA 42 21.9 37 19.1 1.01 0.57 1.77 0.99 
Met carrier GG 11 7.1 9 5.4 1.00* - - -
GA 75 48.1 84 50.6 1.37 0.54 3.48 0.51 
AA 70 44.9 73 44.0 1.27 0.50 3.26 0.61 
MTHFR rs1801133 rs1801131 n % n %
CC AA 72 55.4 63 50.4 1.00* - - -
CA 50 38.5 55 44.0 1.26 0.75 2.10 0.38 
CC 8 6.2 7 5.6 1.00 0.34 2.91 1.00 
CT+TT AA 167 76.6 185 78.7 1.00* - - -
CA 50 22.9 50 21.3 0.90 0.58 1.41 0.65 
CC 1 0.5 0 0 - - - -6
cated in an inefficient prefrontal working memory response
during a working memory paradigm in healthy control sub-
jects [36]. In our analysis of the combination of COMT Val158-
Met and rs165599, we found no interactive effect in the pati-
ents and control subjects.
A number of studies including a meta-analysis have sug-
gested an association between schizophrenia and MTHFR
C677T, and A1298C and schizophrenia [15-17]. Zintzaras
reported that the C677T association was only of marginal
significance in an East Asian population, with a fixed effects
odds ratio of 1.23 (1.00-1.52), whereas for Caucasians the
results were non-significant [18]. However, there was no asso-
ciation between two MTHFR functional SNPs and schizophre-
nia risk in our study. Such inconsistent results may be due to
the ethnic diversity in terms of allele frequency and exposure
to environmental factors, warranting further studies. 
Finally, we also carried out an association analysis on the
effect of two genetic variants of enzymes of the methylation
pathway, the COMT Val158Met and MTHFR C677T poly-
morphisms, on schizophrenia risk. MTHFR C677T may con-
tribute to COMT gene regulation, wherein T-allele carriers
exhibit diminished promoter methylation, increased COMT
expression, and reduced dopamine signaling [22]. Roffman et
al. reported that the MTHFR T allele undermines category
generation in schizophrenia, with 33% of T/T patients unable
to complete a single category, and then reported that COMT
Val108/158Met does not significantly influence this aspect of
executive function, by itself or in interaction with MTHFR
C677T [35, 37]. However, that study had several limitations
such as the number of subjects, especially for a gene interac-
tion study, and the results require replication in other sam-
ples. Our study revealed that no association between COMT
158Val genotype combined with the MTHFR 677TT within
patient and controls. Therefore, the genetic interaction of the
COMT Val158Met and MTHFR C677T genotype may con-
tribute to executive function deficits in schizophrenia [37].
The limitations of our study include the small sample size,
the lack of sub-classification of schizophrenia, and the lack of
adjustment for potential confounders. Our study had a power
of >70% in each gene to detect an odds ratio of ≥1.5 (assum-
ing a dominant effect, with a minor allele frequency of 0.1 and
a=0.05). However, we note that further studies are required
on a larger number of subjects and compressive approach for
the COMT and MTHFR genes in the Korean population. 
In conclusion, our results suggest no significant association
between any of the selected functional polymorphisms of
COMT or MTHFR in Korean schizophrenia subjects. Howev-
er, further studies are required to confirm our findings in a
larger number of subjects. 
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